Armstrong Shaw Associates Incct Lowers stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Armstrong Shaw Associates Incct reduced its stake in AbbVie Inc by 0.1% during the most recent quarter end. The investment management company now holds a total of 206,510 shares of AbbVie Inc which is valued at $13,825,845 after selling 205 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.AbbVie Inc makes up approximately 3.38% of Armstrong Shaw Associates Incct’s portfolio.

Other Hedge Funds, Including , Ashfield Capital Partners reduced its stake in ABBV by selling 364 shares or 0.32% in the most recent quarter. The Hedge Fund company now holds 113,822 shares of ABBV which is valued at $7,620,383. AbbVie Inc makes up approx 0.58% of Ashfield Capital Partners’s portfolio.Brown Advisory Securities boosted its stake in ABBV in the latest quarter, The investment management firm added 838 additional shares and now holds a total of 42,157 shares of AbbVie Inc which is valued at $2,805,127. AbbVie Inc makes up approx 0.85% of Brown Advisory Securities’s portfolio.Northstar Investment Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 1,259 additional shares and now holds a total of 115,685 shares of AbbVie Inc which is valued at $7,697,680. AbbVie Inc makes up approx 1.76% of Northstar Investment Advisors’s portfolio.Palisade Asset Management boosted its stake in ABBV in the latest quarter, The investment management firm added 892 additional shares and now holds a total of 59,256 shares of AbbVie Inc which is valued at $3,838,011. AbbVie Inc makes up approx 0.71% of Palisade Asset Management’s portfolio.

AbbVie Inc opened for trading at $67.47 and hit $68.1239 on the upside on Monday, eventually ending the session at $67.39, with a gain of 0.30% or 0.2 points. The heightened volatility saw the trading volume jump to 52,15,360 shares. Company has a market cap of $109,747 M.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.